Our Portfolio
Direct Investments
We take an active role in our portfolio companies, contributing expertise in drug discovery, development and operations, to help them deliver maximum patient value.
AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline
EsoBiotec is a biotechnology company developing an in vivo engineering platform to produce cancer fighting cells inside the patient’s body.
Neurona is a cell therapy company focused on the development of breakthrough treatments for neurological disorders
Walden Biosciences, Inc., a biotechnology company focused on transforming the treatment of kidney disease.
StrideBio, Inc. is a gene therapy company focused on creating and developing novel adeno-associated viral (AAV) vector technologies.
Rinri Therapeutics is a biotechnology company developing advanced stem cell-based therapeutics to treat hearing loss.
Locana, Inc. is an RNA-targeting gene therapy company with a platform technology to address a wide spectrum of human genetic diseases.
Ally Therapeutics
Ally Therapeutics is a gene therapy company spun out of Harvard.
Syndesi Therapeutics is developing novel modulators of the synaptic vesicle protein SV2A to address disorders of cognition.
ExeVir Bio is an VHH antiviral platform company focused on rapid control with a lead compound for COVID-19.
Selected Invested Funds
arixbioscience.comarixbioscience.com Arix Bioscience supports medical innovation at all stages of development and has access to breakthrough academic science.
pappas-capital.comaPappas is dedicated to furthering life science discoveries and delivering groundbreaking solutions to market.
qimingvc.comQiming drives innovation and growth of business enterprises and promotes overall industry advancement and social development.
